Might it be worth Researchers taking another look at this, in conjunction with the Rituximab data? " Introduction Therapy with high-dose intravenous immunoglobulin (IVIG) has been demonstrated to be useful in several diseases, from autoimmunity mediated by autoantibodies (such as Guillain-Barré syndrome, myasthenia gravis, etc) to primary and secondary antibody deficiency states. It has also been recommended in inflammatory conditions (myopathies) and in some infectious diseases (viral pneumonitis after transplantation, severe or recurrent Clostridium difficile colitis) (UK Guidelines, 2009). This kind of treatment is sometimes offered to ME/CFS patients too, with a wide range of doses, frequency and number of administrations. In what follows I have searched for trials of IVIG in ME/CFS patients, seeking for evidences of efficacy." https://paolomaccallini.wordpress.c...mmunoglobulin-therapy-in-patients-with-mecfs/ although this writer who compares a number of studies comes to the conclusion that "These three controlled trials do not seem to support the use of IVIG in ME/CFS, even if there is some data in favour of the use of the highest dosage (2g/kg/month) in patients with low CD4 count." most of the research seems to have been on small samples, a while ago (1 on children). I am sure there are more positive/promising reports out there.